Acadian Asset Management
CARM

Acadian Asset Management’s Carisma Therapeutics CARM Stock Holding History

Acadian Asset Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,665
Closed -$361K – 1755
2022
Q4 		$361K Buy
29,665
+23,196
+359% +$244K ﹤0.01% 1131
2022
Q3 		$54K Buy
+6,469
New +$88.1K ﹤0.01% 1487
2021
Q2 		– Sell
-7,595
Closed -$396K – 2014
2021
Q1 		$396K Buy
+7,595
New +$358K ﹤0.01% 1274

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management's CARM Position: Q1 2023 in Review

Acadian Asset Management sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 29,665 shares — an estimated $361K sold.

Acadian Asset Management first reported a position in CARM in Q1 2021 and held it in 3 quarters. The position peaked at $396K in Q1 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

  • Acadian Asset Management reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Acadian Asset Management sold 29,665 Carisma Therapeutics shares in Q1 2023, an estimated $361K.
  • Acadian Asset Management first reported a position in Carisma Therapeutics in Q1 2021 and held it in 3 quarters.
  • Acadian Asset Management's Carisma Therapeutics position peaked at $396K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Acadian Asset Management's 13F filing for Q1 2023, filed 11 May 2023.